Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, TX
Treatments:ChemotherapyHospital:University of Texas MD Anderson Cancer Center
Drugs:Journal:Link
Date:Nov 2008

Description:

Patients: This phase 2 study involved 50 women with metastatic breast cancer. The median age was 50, ranging from 26 to 73 years of age.

Treatment: Patients were treated with the chemotherapy drugs gemcitabine and irinotecan.

Toxicity: Grade 4 neutropenia was reported in four patients, and grade 4 leukopenia was reported in one. Grade 3 toxicities included decreased hemoglobin, leucopenia, lymphopenia, neutropenia, low platelet count, fatigue, diarrhea and nausea.

Results: The median overall survival was 11.6 months.

Support: This study was supported in part by funds from Pfizer, which markets irinotecan as CAMPTOSAR.

Correspondence: Dr. Stacy Moulder



Back